British American Tobacco
Global tobacco giant selling cigarettes, vapes, and nicotine pouches under Vuse, glo, and Velo.
BAT's cigarette profits are shrinking slowly while it races to make nicotine pouches and vapes big enough to replace them before regulators or Philip Morris close the gap.
British American Tobacco makes cigarettes and smokeless tobacco products sold in 35 countries. It is hard to replace because governments tightly control tobacco through licenses and advertising rules that protect existing large companies like BAT, and because the company owns factories and distribution networks across many countries. However, Philip Morris is winning customers faster with products like IQOS (heated tobacco) and ZYN (pouches), and BAT's old cigarette business is shrinking. The key question is whether BAT can grow its newer smokeless products fast enough to make up for cigarette sales falling, and whether governments will change the rules in ways that hurt it.
Fit2Win workforce cuts (5,500 layoffs, 3,500 outsourced) proceed without major strikes or regulatory blocks by early 2027. Shows restructuring savings target of £600m by 2028 is executing as planned.
FDA issues final rule on foreign tobacco maker oversight affecting BAT's US imports/manufacturing. Would signal rising compliance costs or import restrictions on BAT's US operations.
- New Categories revenue hit £3.62bn in 2025
- Combustible volumes declining ~2.5%/year
- Fit2Win targets £600m savings by 2028
- Labor and regulatory backlash from ~20% workforce cut announced 2026-06-29.
- Combustible decline accelerating past 5%/year would break New Category transition economics.
- Illicit vape trade continuing to erode Vuse vapour revenue in US and Canada.
- FDA rulemaking tightening oversight of foreign tobacco makers could raise compliance costs.
- Canada CCAA litigation settlement creates ongoing multi-year cash-flow drag.
| Rival | Direction | Evidence |
|---|---|---|
| Philip Morris International | losing to | PMI ~$38.2bn net sales 2025 vs BAT #2 rank, per Statista 2025-11-04 |
| Philip Morris International (ZYN) | contesting | BAT's Velo Plus reached #2 US modern oral within a year, as of 2026-02-24, behind ZYN |
| Illicit vape trade (US/Canada) | losing to | Vuse vapour revenue fell ~9-10.4% in 2025 due to illicit single-use vapes |
| China National Tobacco Corporation | contesting | State monopoly holds ~98% of China market, outside Big 5 competitive dynamics |
| Imperial Brands / JTI / Altria | contesting | Big 5 collectively hold ~80% global share as of 2026-03-31 |
- Is British American Tobacco profitable in 2026?
- Yes. BAT reported FY2025 group revenue of £25.61 billion and adjusted profit from operations up 3.4% to roughly £11.6-11.9 billion (adjusted for Canada), as of results reported 2026-02-24. Guidance targets 3-5% revenue and 4-6% profit growth for FY2026.
- Is British American Tobacco laying off workers?
- Yes. On 2026-06-29 BAT announced plans to cut about 20% of its workforce: 5,500 job cuts plus outsourcing of 3,500 roles, under an explicitly AI-driven 'Fit2Win' transformation programme targeting roughly £600 million in annual savings by 2028.
- Could AI replace British American Tobacco's core business?
- No. BAT's core business relies on FDA licensing, integrated manufacturing across 67 facilities in 35 markets, and entrenched retail distribution, none of which AI can originate. As of 2026-06-29, BAT uses AI internally to cut back-office costs, not as a threat to its product moat.
- Who is British American Tobacco's biggest competitor?
- Philip Morris International, the world's largest tobacco company with about $38.2 billion in net sales in 2025 (as of 2025-11-04), competing directly via IQOS in heated tobacco and ZYN in modern oral nicotine pouches against BAT's glo and Velo.
- Who owns British American Tobacco?
- BAT is publicly traded with no controlling parent; top institutional shareholders as of 2026-05-29 include BlackRock (about 7.2-8.3%), Vanguard Group (about 5.2%), and Fidelity/FMR (about 5-5.8%), per Investing.com's ownership data.
- Is British American Tobacco's vaping business (Vuse) declining?
- Vapour revenue fell about 9-10.4% to £1,542 million in 2025 due to illicit single-use vapes in the US and Canada, but H2 2025 showed a Vuse US recovery, and Vuse remains BAT's top global vaping brand by value share, per BAT's 2025 performance summary.
- 2026-06-29BAT announces Fit2Win: ~20% workforce cut (5,500 layoffs, 3,500 outsourced), AI-driven cost programme
- 2026-06-08BAT reports 47,000+ employees, 67 facilities in 35 markets in company at-a-glance update
- 2026-06-03H1 2026 update: New Categories growth accelerates to mid-teens, BAT claims fastest-growing US nicotine business
- 2026-02-24FY2025 results: revenue £25.61bn, adjusted profit up 3.4%, guidance for 3-5% revenue growth in 2026
- 2025-08-29BAT settles all outstanding Canadian tobacco litigation via CCAA process
- 2025-03-12Canadian CCAA court sanction reported; BAT commits £900m to 2025 share buyback
- 2025-03BAT launches Vuse Ultra, premium vape with Bluetooth and Flavour AutoTune chip
- 2023-12BAT commits to Building a Smokeless World, targeting >50% smokeless revenue by 2035
- British American Tobacco (Wikipedia) (2026-07-20)
- Leading tobacco companies worldwide based on net sales 2025 (2025-11-04)
- BTI Reports 2025 Revenue, Profit Growth (2026-02-24)
- BAT posts 2025 results with modest growth (2026-02-12)
- BAT at-a-glance (2026-06-08)
- Yahoo Finance (2026-02-24)
- 2025 Combined Summary
- BAT: New Categories Accelerating (2026-06-03)
- BAT to cut thousands of jobs in AI cost-saving programme (2026-06-29)
- BAT homepage/press release (2026-06-29)
- BAT Vuse page (2026-04-08)
- 2026 First Half Pre-Close Trading Update (2026-07-14)